Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 25:7:1349-59.
doi: 10.2147/OTT.S48443. eCollection 2014.

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

Scott S Tykodi  1
Affiliations
Review

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

Scott S Tykodi. Onco Targets Ther. .

Abstract

Renal cell carcinoma (RCC) is the most common primary malignant tumor of the kidney in adults, representing approximately 4% of all adult cancers in the United States. Metastatic RCC is poorly responsive to conventional cytotoxic chemotherapies but can be sensitive to T-cell-directed immunotherapies such as interferon-α or interleukin-2. Despite recent progress in the application of antiangiogenic "targeted therapies" for metastatic RCC, high-dose interleukin-2 remains an appropriate first-line therapy for select patients and is associated with durable complete remissions in a small fraction of treated patients. Thus, advanced RCC provides a unique opportunity to investigate the requirements for effective antitumor immunotherapy. Accumulating evidence suggests that resistance mechanisms exploited by RCC and other tumor types may play a dominant role in limiting the effectiveness of tumor-reactive adaptive immune responses. Expression of the inhibitory coreceptor programmed cell death-1 (PD-1) on tumor-infiltrating lymphocytes within RCC tumors, as well as the expression of the PD-1 ligand (PD-L1) on RCC tumor cells, are strong negative prognostic markers for disease-specific death in RCC patients. Monoclonal antibodies targeting either PD-1 or PD-L1 have now entered clinic trials and have demonstrated promising antitumor effects for refractory metastatic RCC. This review summarizes the results of published and reported studies of PD-1- and PD-L1-targeted therapies enrolling patients with advanced RCC, focusing on key safety, toxicity, and efficacy end points. Prospects for advanced phase clinical testing and novel therapy combinations with PD-1- and PD-L1-targeted agents are discussed.

Keywords: PD-1; PD-L1; T-lymphocyte; immune checkpoint; immunotherapy; renal cell carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Stimulatory and Inhibitory coreceptors regulate T-cell responses to tumor antigens. Notes: Tumor antigen recognition by T-cells is dependent on T-cell receptor (TCR) recognition of a peptide ligand major histocompatibility complex (MHC). Following TCR engagement, T-cell activation and acquisition of effector functions requires costimulatory signals mediated by CD28 binding to a B7 family molecule (B7.1 or B7.2) on the antigen-presenting cell (APC). Activation-induced upregulation of inhibitory receptors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and others then acts to downmodulate T-cell effector functions when engaged with cognate ligands. CTLA-4 competes with CD28 for binding to B7 molecules expressed on APCs, an interaction occurring during T-cell priming in lymphoid tissues. PD-1 binds to its ligands PD-L1 or PD-L2. PD-L1 expression is upregulated on tumor cells by interferons or other stimuli within the tumor microenvironment that may allow tumor cells to evade an endogenous immune response. Antibody blockade or PD-1 or PD-L1 may augment the activity of T-cells specific for tumor antigens. From The New England Journal of Medicine, Ribas A, Tumor Immunotherapy Directed at PD-1, 366, Page No 2518. Copyright © (2012) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Figure 2
Figure 2
Programmed cell death-ligand 1 (PD-L1; or B7-H1) expression on clear cell renal cell carcinoma tumor is associated with cancer-specific death. Notes: The expression of PD-L1 (B7-H1) detected on formalin-fixed paraffin-embedded tumor samples by immunostaining with the 5H1 antibody was analyzed on 306 clear cell tumors. Positive PD-L1 expression (≥5% of tumor cells) was seen in 24% of tumors. The risk ratio for cancer-specific death in patients with PD-L1+ tumors was 3.92 (95% confidence interval 2.61–5.88; P<0.001). Adapted from Cancer Research, Copyright 2006, 66(7), 3381–3385, Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up, with permission from AACR.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Papac RJ. Spontaneous regression of cancer. Cancer Treat Rev. 1996;22(6):395–423. - PubMed
    1. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9(12):4296–4303. - PubMed
    1. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. - PubMed
    1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. - PMC - PubMed
    1. Amato RJ, Hawkins RE, Kaufman HL, et al. Vaccination of metastatic renal cancer patients with MVA–5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010;16(22):5539–5547. - PubMed